NCT05855668 Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
| NCT ID | NCT05855668 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre for Addiction and Mental Health |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-11-10 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2022-11-10 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This 2-arm study will recruit participants with 1) alcohol use disorder and 2) cannabis use disorder for a 12-week cognitive behavioral therapy, following a thorough baseline assessments on executive function, incentive salience, and negative emotionality.
Eligibility Criteria
Inclusion Criteria: 1. Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy). 2. Able to communicate and provide informed consent in English. 3. 18 years of age or older. 4. Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments. 5. Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group) 6. Meets criteria for risky drinking, defined as \> 10 drinks per week for females and \> 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days, defined as ≥ 4 days of cannabis use per week on average (CUD group) Exclusion Criteria: 1. Active suicidal ideation at time of assessment. 2. Suicide attempt within the past month. 3. Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use). 4. Enrollment in another study that conflicts with the procedures or scientific integrity of this study. 5. Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.
Contact & Investigator
Matthew Sloan, MD
PRINCIPAL INVESTIGATOR
Centre for Addiction and Mental Health
Frequently Asked Questions
Who can join the NCT05855668 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05855668 currently recruiting?
Yes, NCT05855668 is actively recruiting participants. Contact the research team at Kelly.Xiao@camh.ca for enrollment information.
Where is the NCT05855668 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05855668 clinical trial?
NCT05855668 is sponsored by Centre for Addiction and Mental Health. The principal investigator is Matthew Sloan, MD at Centre for Addiction and Mental Health. The trial plans to enroll 400 participants.